Blood Test for Ovarian Cancer

The OVA1 blood test had a high chance of correctly identifying whether an ovarian mass was malignant prior to surgery, according to results of the OVA500 clinical trial. In a study of 494 patients, the test had 94% sensitivity in premenopausal women and 91% sensitivity in the early-stage ovarian cancer [ Read More ]

Older Patients With Mantle Cell Lymphoma

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy followed by maintenance therapy with rituximab was more effective than R-FC (rituximab, fludarabine, and cyclophosphamide) followed by maintenance therapy with interferon alfa in older patients with mantle cell lymphoma, according to a recently published prospective, randomized, double-blind clinical trial (Kluin-Nelemans HC, [ Read More ]

Team Approach Enhances Choice of Observation in Men With Low-Risk Prostate Cancer

Men diagnosed with low-risk prostate cancer are more likely to choose active surveillance as their primary treatment if their care is managed by a multidisciplinary team, according to a recent study published online ahead of print July 30, 2012, in the Journal of Clinical Oncology. In 2012, about 240,000 men [ Read More ]

Surgery Versus Observation for Localized Prostate Cancer

For men with localized prostate cancer detected by prostate-specific antigen (PSA) level, treatment with radical prostatectomy did not significantly reduce mortality compared with observation, according to overall results of the large, randomized, controlled PIVOT trial (Wilt TJ, et al. N Engl J Med. 2012; 367:203-213). All-cause mortality and prostate-specific mortality [ Read More ]

Facilitating the Next Generation of Precision Medicine in Oncology

Key Points Key stakeholders are increasingly considering new measures to protect and advance innovation and investment in diagnostics Efforts are under way to establish more appropriate and least burdensome regulatory policies to address stakeholder concerns specific to in vitro diagnostic tests FDA is concerned with the risk of false-positive and [ Read More ]

Prostate Cancer Roundup

Nearly 3000 abstracts were selected for presentation at the recent ASCO 2012 Annual Meeting, many of them related to some aspect of personalized medicine. Below are some highlights selected from the meeting that focus on potential genomic predictors of aggressive versus indolent disease and on potential biomarkers. 6-Gene Model Identifies [ Read More ]

New Targeted Therapies and New Biomarkers Explored at ASCO 2012

Below are some highlights of presentations at the 2012 ASCO Annual Meeting related to targeted therapies and personalized (precision) medicine. T-DM1 The anti-body drug conjugate T-DM1 significantly prolonged progression-free survival (PFS) compared with standard capecitabine/lapatinib therapy for treatment of advanced HER2-positive breast cancer in the EMILIA trial (Abstract LBA1). Median [ Read More ]

Rapid Changes in Reimbursement Protocols for Molecular Tests

Molecular tests have proliferated over the past decade, bringing the precision of genomics into reality in the clinic, but the payment system for nucleic acid–based tests has been unchanging and primitive. This unfortunate state of affairs has limited the ability of payers to encourage (or control) the use of genomic [ Read More ]

Implementing the Promise of Personalized Cancer Care

To receive credit, complete the posttest at www.mlicme.org/P11077.html.   Until recently, cancer treatment relied solely on histologic diagnosis for determining systemic therapy. Aside from considerations related to a patient’s underlying comorbidities and performance status, there was minimal deviation from an organ-of-origin–based treatment strategy. This relatively primitive understanding of malignancy failed [ Read More ]

Personalized Medicine Advances in Melanoma: An Interview With K. Peter Hirth, PhD

Plexxikon, a member of the Daiichi Sankyo Group since 2011, works in the structureguided discovery and development of novel small-molecule pharmaceuticals to treat human disease. The company’s lead drug Zelboraf (vemurafenib/PLX4032) was approved by the FDA in August 2011 and is copromoted in the United States by Daiichi Sankyo, Inc. [ Read More ]

Sign me up!